{"id":538615,"date":"2021-04-14T19:26:01","date_gmt":"2021-04-14T19:26:01","guid":{"rendered":"https:\/\/www.abnewswire.com\/pressreleases\/?p=538615"},"modified":"2021-04-14T19:26:01","modified_gmt":"2021-04-14T19:26:01","slug":"exosomes-pipeline-emerging-therapies-and-key-pharma-players-involved-by-delveinsight-direct-biologics-codiak-biosciences-exocyte-therapeutics-avalon-globocare-united-therapeutics","status":"publish","type":"post","link":"https:\/\/www.abnewswire.com\/pressreleases\/exosomes-pipeline-emerging-therapies-and-key-pharma-players-involved-by-delveinsight-direct-biologics-codiak-biosciences-exocyte-therapeutics-avalon-globocare-united-therapeutics_538615.html","title":{"rendered":"Exosomes Pipeline: Emerging Therapies and Key pharma players involved by DelveInsight | Direct Biologics, Codiak BioSciences, ExoCyte Therapeutics, Avalon GloboCare, United Therapeutics"},"content":{"rendered":"<div style=\"float:right; width:250px; padding:8px 10px 10px 10px;\"><a href=\"https:\/\/www.abnewswire.com\/uploads\/1585720511.jpeg\" style=\"border:none !important;\" target=\"_blank\" rel=\"nofollow\" ><img loading=\"lazy\" decoding=\"async\" class=\"alignnone size-medium wp-image-29\" title=\"Exosomes Pipeline: Emerging Therapies and Key pharma players involved by DelveInsight | Direct Biologics, Codiak BioSciences, ExoCyte Therapeutics, Avalon GloboCare, United Therapeutics\" src=\"https:\/\/www.abnewswire.com\/uploads\/1585720511.jpeg\" alt=\"Exosomes Pipeline: Emerging Therapies and Key pharma players involved by DelveInsight | Direct Biologics, Codiak BioSciences, ExoCyte Therapeutics, Avalon GloboCare, United Therapeutics\" width=\"225\" height=\"225\" style=\"padding:0px 0px 10px 10px; border:0 solid !important;\" \/><\/a><\/p>\n<div class=\"quotes\">\n<div>Exosomes Pipeline<\/div>\n<\/div>\n<\/div>\n<p style=\"text-align: justify;\"><strong>Exosomes&nbsp;<\/strong>are small membrane vesicles of endocytic origin that are secreted by most cells in culture and are created upon the fusion of the multivesicular body (MVB)&mdash;an intermediate endocytic compartment&mdash;with the plasma membrane. They are nano-sized vesicles capable of transferring DNAs, micro RNAs, non-coding RNAs, and lipids, with or without direct cell-to-cell contact, which represents a novel method of intracellular communication. MVB&mdash;a type of intraluminal vesicles (ILV&rsquo;s)&mdash;buds inward into the endosomal lumen.<\/p>\n<p style=\"text-align: justify;\">DelveInsight&rsquo;s,<strong>&ldquo;<a rel=\"nofollow\" href=\"https:\/\/www.delveinsight.com\/report-store\/exosomes-pipeline-insight?utm_source=SatPR&amp;utm_medium=pressrelease&amp;utm_campaign=apr\">Exosomes Pipeline<\/a> Insight, 2021&rdquo;&nbsp;<\/strong>report provides comprehensive insights about 50+ companies and 50+ pipeline drugs in Exosomes pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.<\/p>\n<p style=\"text-align: justify;\">&nbsp;<\/p>\n<p style=\"text-align: justify;\"><strong>Request for free sample page:&nbsp;<a rel=\"nofollow\" href=\"https:\/\/www.delveinsight.com\/sample-request\/exosomes-pipeline-insight?utm_source=SatPR&amp;utm_medium=pressrelease&amp;utm_campaign=apr\">https:\/\/www.delveinsight.com\/sample-request\/exosomes-pipeline-insight<\/a><\/strong><\/p>\n<p style=\"text-align: justify;\">&nbsp;<\/p>\n<p style=\"text-align: justify;\"><strong>Some of <\/strong><strong>Exosomes Companies<\/strong><strong>:<\/strong><\/p>\n<ul style=\"text-align: justify;\">\n<li>Direct Biologics<\/li>\n<li>Codiak BioSciences<\/li>\n<li>ExoCyte Therapeutics<\/li>\n<li>Avalon GloboCare<\/li>\n<li>United Therapeutics Corporation<\/li>\n<li>Capricor Therapeutics<\/li>\n<li>Avalon GloboCare<\/li>\n<li>Azymus Therapeutics<\/li>\n<li>Versatope Therapeutics<\/li>\n<li>Lamellar Biomedical<\/li>\n<li>Celltrion<\/li>\n<li>And Many Others<\/li>\n<\/ul>\n<p style=\"text-align: justify;\">&nbsp;<\/p>\n<p style=\"text-align: justify;\"><strong>Request for free sample page: <a rel=\"nofollow\" href=\"https:\/\/www.delveinsight.com\/sample-request\/exosomes-pipeline-insight?utm_source=SatPR&amp;utm_medium=pressrelease&amp;utm_campaign=apr\">https:\/\/www.delveinsight.com\/sample-request\/exosomes-pipeline-insight<\/a><\/strong><\/p>\n<p style=\"text-align: justify;\">&nbsp;<\/p>\n<p style=\"text-align: justify;\"><strong>DelveInsight&rsquo;s report covers around 50+ products under different phases of clinical development like<\/strong><\/p>\n<ul style=\"text-align: justify;\">\n<li>Late-stage products (Phase II and Phase II\/III)<\/li>\n<li>Mid-stage products (Phase II and Phase II\/III)<\/li>\n<li>Early-stage products (Phase I\/II and Phase I) along with the details of<\/li>\n<li>Pre-clinical and Discovery stage candidates<\/li>\n<li>Discontinued &amp; Inactive candidates<\/li>\n<li>Route of Administration<\/li>\n<\/ul>\n<p style=\"text-align: justify;\">&nbsp;<\/p>\n<p style=\"text-align: justify;\"><strong>Some of <a rel=\"nofollow\" href=\"https:\/\/www.delveinsight.com\/report-store\/exosomes-pipeline-insight?utm_source=SatPR&amp;utm_medium=pressrelease&amp;utm_campaign=apr\">Exosomes Therapies<\/a>:<\/strong><\/p>\n<ul style=\"text-align: justify;\">\n<li>LAMELLASOME IPF-NA<\/li>\n<li>exoSTING<\/li>\n<li>ET-08<\/li>\n<li>AVA 201<\/li>\n<li>Unexisome<\/li>\n<li>CAP 2003<\/li>\n<li>exoIL 12<\/li>\n<li>AVA 203<\/li>\n<li>AZ 001<\/li>\n<li>VT 105<\/li>\n<li>And Many Others<\/li>\n<\/ul>\n<p style=\"text-align: justify;\">&nbsp;<\/p>\n<p style=\"text-align: justify;\"><strong>Request for free sample page: <a rel=\"nofollow\" href=\"https:\/\/www.delveinsight.com\/sample-request\/exosomes-pipeline-insight?utm_source=SatPR&amp;utm_medium=pressrelease&amp;utm_campaign=apr\">https:\/\/www.delveinsight.com\/sample-request\/exosomes-pipeline-insight<\/a><\/strong><\/p>\n<p style=\"text-align: justify;\">&nbsp;<\/p>\n<p style=\"text-align: justify;\"><strong>Table of Contents:<\/strong><\/p>\n<p style=\"text-align: justify;\">Introduction<\/p>\n<p style=\"text-align: justify;\">Executive Summary<\/p>\n<p style=\"text-align: justify;\">Exosomes: Overview<\/p>\n<p style=\"text-align: justify;\">Formation<\/p>\n<p style=\"text-align: justify;\">Exosomes in CNS Disease<\/p>\n<p style=\"text-align: justify;\">Exosomes in Oncology<\/p>\n<p style=\"text-align: justify;\">Exosomes in Other Diseases<\/p>\n<p style=\"text-align: justify;\">&bull; Advantages and disadvantages<\/p>\n<p style=\"text-align: justify;\">Pipeline Therapeutics<\/p>\n<p style=\"text-align: justify;\">&bull; Comparative Analysis<\/p>\n<p style=\"text-align: justify;\">Therapeutic Assessment<\/p>\n<p style=\"text-align: justify;\">Exosomes &ndash; DelveInsight&rsquo;s Analytical Perspective<\/p>\n<p style=\"text-align: justify;\">In-depth Commercial Assessment<\/p>\n<p style=\"text-align: justify;\">&bull; Exosomes companies&rsquo; collaborations, Licensing, Acquisition -Deal Value Trends<\/p>\n<p style=\"text-align: justify;\">Exosomes Collaboration Deals<\/p>\n<p style=\"text-align: justify;\">Mid Stage Products (Phase I\/II)<\/p>\n<p style=\"text-align: justify;\">&bull; Comparative Analysis<\/p>\n<p style=\"text-align: justify;\">MPCs-derived exosomes: Cellular Biomedicine Group Ltd.<\/p>\n<p style=\"text-align: justify;\">Pre-clinical and Discovery Stage Products<\/p>\n<p style=\"text-align: justify;\">&bull; Comparative Analysis<\/p>\n<p style=\"text-align: justify;\">exoSTING: Codiak BioSciences<\/p>\n<p style=\"text-align: justify;\">AVA 201: Avalon GloboCare<\/p>\n<p style=\"text-align: justify;\">UNEX 42: United Therapeutics Corporation<\/p>\n<p style=\"text-align: justify;\">CAP 2003: Capricor Therapeutics<\/p>\n<p style=\"text-align: justify;\">AB 126: ArunA Biomedical<\/p>\n<p style=\"text-align: justify;\">Drug profiles in the detailed report&hellip;..<\/p>\n<p style=\"text-align: justify;\">Inactive Products<\/p>\n<p style=\"text-align: justify;\">&bull; Comparative Analysis<\/p>\n<p style=\"text-align: justify;\">Exosomes Key Companies<\/p>\n<p style=\"text-align: justify;\">Exosomes Key Products<\/p>\n<p style=\"text-align: justify;\">Exosomes- Unmet Needs<\/p>\n<p style=\"text-align: justify;\">Exosomes- Market Drivers and Barriers<\/p>\n<p style=\"text-align: justify;\">Exosomes- Future Perspectives and Conclusion<\/p>\n<p style=\"text-align: justify;\">Exosomes Analyst Views<\/p>\n<p style=\"text-align: justify;\">Exosomes Key Companies<\/p>\n<p style=\"text-align: justify;\">Appendix<\/p>\n<p style=\"text-align: justify;\"><strong>Request for Deatiled TOC: https:\/\/www.delveinsight.com\/sample-request\/exosomes-pipeline-insight<\/strong><\/p>\n<p style=\"text-align: justify;\"><strong>&nbsp;<\/strong><\/p>\n<p style=\"text-align: justify;\"><strong>About&nbsp;DelveInsight<\/strong><br \/> DelveInsight is a leading Business Consultant, and Market Research Firm focused exclusively on life sciences. It supports pharma companies by providing end-to-end comprehensive solutions to improve their performance.<\/p>\n<p><span style='font-size:18px !important;'>Media Contact<\/span><br \/><strong>Company Name:<\/strong> <a href=\"https:\/\/www.abnewswire.com\/companyname\/delveinsight.com_56434.html\" rel=\"nofollow\">DelveInsight Business Research LLP<\/a><br \/><strong>Contact Person:<\/strong> Ankit Nigam<br \/><strong>Email:<\/strong> <a href=\"https:\/\/www.abnewswire.com\/email_contact_us.php?pr=exosomes-pipeline-emerging-therapies-and-key-pharma-players-involved-by-delveinsight-direct-biologics-codiak-biosciences-exocyte-therapeutics-avalon-globocare-united-therapeutics\" rel=\"nofollow\">Send Email<\/a><br \/><strong>Phone:<\/strong> +19193216187<br \/><strong>Address:<\/strong>304 S. Jones Blvd #2432  <br \/><strong>City:<\/strong> Albany<br \/><strong>State:<\/strong> New York<br \/><strong>Country:<\/strong> United States<br \/><strong>Website:<\/strong> <a href=\"https:\/\/www.delveinsight.com\/report-store\/exosomes-pipeline-insight\" target=\"_blank\" rel=\"nofollow\">https:\/\/www.delveinsight.com\/report-store\/exosomes-pipeline-insight<\/a><\/p>\n<p><object type=\"text\/html\" data=\"https:\/\/www.delveinsight.com\/report-store\/exosomes-pipeline-insight\" style=\"width:900px; height:400px;\"><\/object><img decoding=\"async\" src=\"https:\/\/www.abnewswire.com\/press_stat.php?pr=exosomes-pipeline-emerging-therapies-and-key-pharma-players-involved-by-delveinsight-direct-biologics-codiak-biosciences-exocyte-therapeutics-avalon-globocare-united-therapeutics\" alt=\"\" width=\"1px\" height=\"1px\" \/><\/p>\n","protected":false},"excerpt":{"rendered":"<p>Exosomes Pipeline Exosomes&nbsp;are small membrane vesicles of endocytic origin that are secreted by most cells in culture and are created upon the fusion of the multivesicular body (MVB)&mdash;an intermediate endocytic compartment&mdash;with the plasma membrane. They are nano-sized vesicles capable of &hellip; <a href=\"https:\/\/www.abnewswire.com\/pressreleases\/exosomes-pipeline-emerging-therapies-and-key-pharma-players-involved-by-delveinsight-direct-biologics-codiak-biosciences-exocyte-therapeutics-avalon-globocare-united-therapeutics_538615.html\">Continue reading <span class=\"meta-nav\">&rarr;<\/span><\/a><\/p>\n","protected":false},"author":1,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[401,405,417,406,423],"tags":[],"class_list":["post-538615","post","type-post","status-publish","format-standard","hentry","category-Business","category-Health-Medicine","category-Marketing-Sales","category-Pharmaceuticals-Biotech","category-Professional-Services"],"_links":{"self":[{"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/posts\/538615","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/comments?post=538615"}],"version-history":[{"count":0,"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/posts\/538615\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/media?parent=538615"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/categories?post=538615"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/tags?post=538615"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}